Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MenACWY-TT Booster 10 Years Post-Primary
NCT03189745Phase 3Completed
- Sponsor
- Pfizer
- Start
- Aug 2017
- Primary completion
- Apr 2018
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of Neisseria meningitidis group C capsular polysaccharide tetanus toxoid conjugate antigen in meningococcal disease, sponsored by Pfizer. Primary endpoint: Percentage of Participants With Booster Response in Terms of Serum Bactericidal Assay Using Rabbit Complement (rSBA) Titer Levels. Started Aug 2017; status: completed.
02
Drugs
Neisseria meningitidis group C capsular polysaccharide tetanus toxoid conjugate antigen
03
Conditions
meningococcal disease
Beyond the preview
Go deeper on NCT03189745.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03189745.